The fraction targeting the CD40 receptor was observed to inhibit the CD40L-induced pro-survival signaling pathways, subsequently diminishing the resistance of Chronic Lymphocytic Leukemia (CLL) cells toward Bcl-2 inhibitors. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.